Siena, Italy, March 15, 2022 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, will announce its Full Year Results for the year ended 31 December 2021 following a Board of Director’s meeting to be held on 28 March 2022.

More detalis